<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893710</url>
  </required_header>
  <id_info>
    <org_study_id>IPPB Biobank</org_study_id>
    <secondary_id>University of Heidelberg</secondary_id>
    <nct_id>NCT01893710</nct_id>
  </id_info>
  <brief_title>International (Pediatric) Peritoneal Biobank</brief_title>
  <official_title>International (Pediatric) Peritoneal Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes&#xD;
      substantial morphological transformation, including progressive fibrosis, vasculopathy and&#xD;
      neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD&#xD;
      failure. In children, peritoneal biopsies demonstrating PD associated alterations have not&#xD;
      yet been obtained. They, however, should be particularly informative, since secondary tissue&#xD;
      and vascular pathology related to ageing or diabetes is absent.&#xD;
&#xD;
      An international, prospective peritoneal membrane biopsy study in children on PD will&#xD;
      therefore be performed. Biopsies will be obtained at time of PD catheter insertion, on&#xD;
      occasion of intercurrent abdominal surgery (e.g. hernia repair, catheter exchange) and at&#xD;
      time of renal transplantation. Quantitative histomorphometry and tissue protein expression&#xD;
      analyses will be correlated with time integrated PD treatment modalities and functional&#xD;
      characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter.&#xD;
      Blood will be obtained during clinical routine sampling. Biopsies will be obtained during&#xD;
      clinically indicated operations, without substantially increasing operation time and&#xD;
      associated surgical risks. The detailed histomorphometry of the PD membrane will give&#xD;
      additional information, potentially impacting on the individual PD regime.&#xD;
&#xD;
      3/2018: The analyses of the pediatric PD biopsy demonstrated early and major transformation&#xD;
      of the peritoneal membrane with neutral pH low GDP fluids, and significant vasculopathy&#xD;
      already in children with CKD stage 5, further progressing with PD. The underlying mechanisms&#xD;
      are partly understood, only. In view of these major findings and the numerous open questions,&#xD;
      collection of biosamples will be continued in children and also in adult PD patients. The&#xD;
      following questions will be addressed: Molecular counterparts of peritoneal&#xD;
      semi-permeability, solute and water transport (beyond AQP1), pathomechanisms and molecular&#xD;
      and functional impact of peritoneal transformation with low and high GDP fluids, and the&#xD;
      respective pathomechanisms and molecular and functional impact of vascular disease in CKD and&#xD;
      with different PD fluids. The impact of renal transplantation following PD will be assessed&#xD;
      in a subgroup of patients with tenckhoff catheter removal several weeks after transplantation&#xD;
      and a functioning graft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see study protocol and&#xD;
&#xD;
      http://www.pedpd.org&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Peritoneal vasculopathy (lumen vessel ratio)</measure>
    <time_frame>Two years (Mean PD treatment time)</time_frame>
    <description>Digital quantification of degree of vasculopathy, i.e the lumen vessel ratio. Healthy children have a L/V ratio of about 0.7. lower values represent vasculopathy with lumen narrowing, 0 is complete obliteration of the vessel.&#xD;
This measurements will be accompanied by molecular analysis of pathomechanisms (including omics Technology)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of vessels per peritoneal membrane area (per mm²)</measure>
    <time_frame>at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation</time_frame>
    <description>Digital histomorphometry of small vessel density per mm² submesothelial section area analysed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Submesothelial thickness (µm)</measure>
    <time_frame>2 years (average PD duration)</time_frame>
    <description>Digital imaging analysis of submesothelial thickness as a marker of peritoneal fibrosis (distance between mesothelium and adjacent muscle/adipos tissue)</description>
  </other_outcome>
  <other_outcome>
    <measure>Submesothelial lymphocyte, macrophage, MMT cell count</measure>
    <time_frame>2 years (mean PD duration)</time_frame>
    <description>Quantification of peritoneal leucocyte Infiltration, i.e. number of CD45 positive lymphocytes and CD68 positive macrophages per mm² of submesothelial section area . The number of cells that underwent mesothelial-mesenchymal transition per mm² submesothelial section are quantified by immunohistochemical co-staining of mesothelial and fibroblast marker (cytokeratin and FSP1).</description>
  </other_outcome>
  <other_outcome>
    <measure>Peritoneal VEGF and pSMAD abundance</measure>
    <time_frame>2 years (mean PD duration)</time_frame>
    <description>Key cytokines involved in peritoneal membrane transformation will be measured immunohistochemically. These are VEGF and TGF-beta induced p-SMAD (%positive area per section area analysed).</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Peritoneal Dialysis Complication</condition>
  <condition>Transplantation</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic kidney disease</arm_group_label>
    <description>Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <description>Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post PD and with functioning graft</arm_group_label>
    <description>Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy sampling</intervention_name>
    <description>Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.&#xD;
Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.</description>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Post PD and with functioning graft</arm_group_label>
    <arm_group_label>chronic kidney disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Parietal ond omental peritoneal membrane specimen will be collected in all groups&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        See eligibility data&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age 0 to 90 years&#xD;
&#xD;
          -  CKD 5D, peritoneal dialysis and&#xD;
&#xD;
          -  Patients with normal renal function and elective abdominal surgery due to limited&#xD;
             abdominal pathology (such as hernia repair, gallstones….)&#xD;
&#xD;
          -  Patients post PD and post Tx&#xD;
&#xD;
          -  Oral and written consent&#xD;
&#xD;
          -  Ability to consent of the adult patient and of the parents and legal guardian of&#xD;
             patients not yet of legal age, respectively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abdominal adhesions, malformation and inflammation beyond PD induced changes&#xD;
&#xD;
          -  Patients with disseminated tumour disease&#xD;
&#xD;
          -  Patients with critical heart failure and other medical conditions, where the&#xD;
             additional procedure may confer an increased increase risk&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Preterm babies (below 37 weeks of gestational age)&#xD;
&#xD;
          -  Serum hemoglobin &lt; 10 g/dl in newborns and &lt; 8 g/dl in children and adults&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus P Schmitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Center for Pediatric and Adolescent Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus P Schmitt, Prof</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>39313</phone_ext>
    <email>claus.peter.schmitt@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley A. Warady, MD</last_name>
      <phone>816-234-3010</phone>
      <email>bwarady@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley A. Warady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children´s Hospital of Philadelphia</name>
      <address>
        <city>Narberth</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Arbeiter, MD</last_name>
      <phone>+43 1404003257</phone>
      <email>klaus.arbeiter@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Arbeiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9890</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Van de Walle, MD</last_name>
      <phone>+32 93322483</phone>
      <email>Johan.VandeWalle@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Johan Van de Walle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Vondrak, MD</last_name>
      <phone>+42 0224432078</phone>
      <email>8080@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Karel Vondrak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique, Hôpital Femme Mere Enfant</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Ranchin, MD</last_name>
      <phone>+33 427856129</phone>
      <email>bruno.ranchin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Ranchin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Zaloszyc, MD</last_name>
      <phone>+333388127742</phone>
      <email>ariane.zaloszyc@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Ariane Zaloszyc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine I (Nephrology), University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Klein, MD</last_name>
      <phone>+49 62215639776</phone>
      <email>katrin.klein@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Taylan, MD</last_name>
      <phone>+49 2214784391</phone>
      <email>christina.taylan@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Christina Taylan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Büscher, MD</last_name>
      <phone>+49 201 723-2738</phone>
      <email>Rainer.Buescher@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Büscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKE, University Children´s Hospital</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Oh, MD</last_name>
      <phone>+49 40 7410 0</phone>
      <email>j.oh@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christian Brix, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KfH Pediatric Kidney Center, Department of Pediatric Nephrology, University of Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Günter Klaus, Prof</last_name>
      <phone>+49 64215862254</phone>
      <email>Guenter.Klaus@kfh-dialyse.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Sallay, MD</last_name>
      <phone>+36 13343186</phone>
      <email>sallay.peter@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Sallay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children'Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Testa, MD</last_name>
      <phone>+39 0257992471</phone>
      <email>saratesta@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Sara Testa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Nephrology, Dialysis and Transplant Unit</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University children's Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <phone>+37 052720427</phone>
      <email>rimantec@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paediatric CAPD unit, Kuala Lumpur Hospital</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakow, Jagiellonian University Medical College</name>
      <address>
        <city>Krakow</city>
        <zip>30663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Drozdz, MD</last_name>
      <phone>+48 12 658 11 59</phone>
      <email>dadrozdz@cm-uj.krakow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Materno-Infantil Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gema Ariceta, MD</last_name>
      <phone>+34 934893082</phone>
      <email>gariceta@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Gema Ariceta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Inselspital, Bern University Hospital and University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aysun K Bayazit, MD</last_name>
      <phone>+90 3223386935</phone>
      <email>ayskar@cu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Aysun K Bayazit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cerrahpasa School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Lebanon</country>
  </removed_countries>
  <link>
    <url>http://www.pedpd.org</url>
    <description>International Pediatric Peritoneal Dialysis Network</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Claus Peter Schmitt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>parietal peritoneum</keyword>
  <keyword>omentum</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>vasculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

